Artiva Biotherapeutics, Inc. Common Stock Total Liabilities
Artiva Biotherapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Artiva Biotherapeutics, Inc. Common Stock (ARTV) has total liabilities worth $19.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ARTV cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Artiva Biotherapeutics, Inc. Common Stock (2019–2024)
Total liabilities of Artiva Biotherapeutics, Inc. Common Stock from 2019 to 2024. This chart illustrates how Artiva Biotherapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Artiva Biotherapeutics, Inc. Common Stoc (ARTV) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Artiva Biotherapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Artiva Biotherapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MHC Plantations Bhd
KLSE:5026
|
Malaysia | RM435.98 Million |
|
IFB Agro Industries Limited
NSE:IFBAGRO
|
India | Rs2.87 Billion |
|
Cisadane Sawit Raya Pt
JK:CSRA
|
Indonesia | Rp1.03 Trillion |
|
Resource Alam Indonesia Tbk
JK:KKGI
|
Indonesia | Rp33.58 Million |
|
Vestel Elektronik Sanayi ve Ticaret AS
IS:VESTL
|
Turkey | TL155.67 Billion |
|
SHEPHERD NEAME P. CONS.
F:43Y
|
Germany | €183.58 Million |
|
CGRE AG
XETRA:CGX
|
Germany | €25.33 Million |
|
Southern Concrete Pile PCL
BK:SCP
|
Thailand | ฿617.65 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Artiva Biotherapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ARTV current and non-current assets.
Liquidity & Leverage Metrics
Artiva Biotherapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Artiva Biotherapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Artiva Biotherapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Artiva Biotherapeutics, Inc. Common Stock (2019–2024)
The table below shows the annual total liabilities of Artiva Biotherapeutics, Inc. Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.94 Million | -91.41% |
| 2023-12-31 | $267.13 Million | -2.42% |
| 2022-12-31 | $273.75 Million | +5.78% |
| 2021-12-31 | $258.78 Million | +409.41% |
| 2020-12-31 | $50.80 Million | +477.35% |
| 2019-12-31 | $8.80 Million | -- |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more